Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States’ FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. It is grouped under the following drug class(es): Antineoplastic agents and LHRH analogues. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Orgovyx, TAK-385 and Ryeqo. Its PubChem CID is 10348973.
Relugolix
| CAS No | 737789-87-6 |
|---|---|
| Molecular Formula | C29H27F2N7O5S |
| Molecular Weight | 623.6 g/mol |
| Synonyms | 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat several hormone-responsive conditions.
The listed CAS number is 737789-87-6.
The listed molecular formula is C29H27F2N7O5S.
The listed molecular weight is 623.6 g/mol.
1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea.
The source lists Orgovyx, TAK-385 and Ryeqo.